A phase 2 study of ibrutinib maintenance following first-line high-dose methotrexate-based chemotherapy for elderly patients with primary central nervous system lymphoma.
Saved in:
| Title: | A phase 2 study of ibrutinib maintenance following first-line high-dose methotrexate-based chemotherapy for elderly patients with primary central nervous system lymphoma. |
|---|---|
| Authors: | Bairey O; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel.; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel., Taliansky A; Institute of Oncology, Neuro-Oncology Unit, Sheba Medical Center, Ramat Gan, Israel., Glik A; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.; Department of Neurology, Cognitive Neurology Clinic, Rabin Medical Center, Petach Tikva, Israel., Amiel A; Neuro-Oncology Center, Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel., Yust-Katz S; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.; Neuro-Oncology Center, Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel., Gurion R; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel.; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel., Zektser M; Institute of Hematology, Soroka Medical Center, Beer-Sheva, Israel., Porges T; Institute of Hematology, Soroka Medical Center, Beer-Sheva, Israel., Sarid N; Institute of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel., Horowitz NA; Department of Hematology and BMT, Rambam Health Care Campus, Haifa, Israel., Shina TT; Institute of Oncology, Neuro-Oncology Unit, Rambam Health Care Campus, Haifa, Israel., Lebel E; Department of Hematology, Hadassah Medical Center, Jerusalem, Israel.; Faculty of Medicine, Hebrew University, Jerusalem, Israel., Cohen A; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel.; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel., Geiger KR; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel., Raanani P; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel.; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel., Wolach O; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel.; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel., Siegal T; Neuro-Oncology Center, Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel.; Faculty of Medicine, Hebrew University, Jerusalem, Israel. |
| Source: | Cancer [Cancer] 2023 Dec 15; Vol. 129 (24), pp. 3905-3914. Date of Electronic Publication: 2023 Aug 12. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 37572086 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: A phase 2 study of ibrutinib maintenance following first-line high-dose methotrexate-based chemotherapy for elderly patients with primary central nervous system lymphoma. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Bairey+O%22">Bairey O</searchLink>; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel.; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.<br /><searchLink fieldCode="AU" term="%22Taliansky+A%22">Taliansky A</searchLink>; Institute of Oncology, Neuro-Oncology Unit, Sheba Medical Center, Ramat Gan, Israel.<br /><searchLink fieldCode="AU" term="%22Glik+A%22">Glik A</searchLink>; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.; Department of Neurology, Cognitive Neurology Clinic, Rabin Medical Center, Petach Tikva, Israel.<br /><searchLink fieldCode="AU" term="%22Amiel+A%22">Amiel A</searchLink>; Neuro-Oncology Center, Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel.<br /><searchLink fieldCode="AU" term="%22Yust-Katz+S%22">Yust-Katz S</searchLink>; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.; Neuro-Oncology Center, Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel.<br /><searchLink fieldCode="AU" term="%22Gurion+R%22">Gurion R</searchLink>; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel.; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.<br /><searchLink fieldCode="AU" term="%22Zektser+M%22">Zektser M</searchLink>; Institute of Hematology, Soroka Medical Center, Beer-Sheva, Israel.<br /><searchLink fieldCode="AU" term="%22Porges+T%22">Porges T</searchLink>; Institute of Hematology, Soroka Medical Center, Beer-Sheva, Israel.<br /><searchLink fieldCode="AU" term="%22Sarid+N%22">Sarid N</searchLink>; Institute of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.<br /><searchLink fieldCode="AU" term="%22Horowitz+NA%22">Horowitz NA</searchLink>; Department of Hematology and BMT, Rambam Health Care Campus, Haifa, Israel.<br /><searchLink fieldCode="AU" term="%22Shina+TT%22">Shina TT</searchLink>; Institute of Oncology, Neuro-Oncology Unit, Rambam Health Care Campus, Haifa, Israel.<br /><searchLink fieldCode="AU" term="%22Lebel+E%22">Lebel E</searchLink>; Department of Hematology, Hadassah Medical Center, Jerusalem, Israel.; Faculty of Medicine, Hebrew University, Jerusalem, Israel.<br /><searchLink fieldCode="AU" term="%22Cohen+A%22">Cohen A</searchLink>; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel.; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.<br /><searchLink fieldCode="AU" term="%22Geiger+KR%22">Geiger KR</searchLink>; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel.<br /><searchLink fieldCode="AU" term="%22Raanani+P%22">Raanani P</searchLink>; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel.; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.<br /><searchLink fieldCode="AU" term="%22Wolach+O%22">Wolach O</searchLink>; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel.; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.<br /><searchLink fieldCode="AU" term="%22Siegal+T%22">Siegal T</searchLink>; Neuro-Oncology Center, Davidoff Cancer Center, Rabin Medical Center, Petach Tikva, Israel.; Faculty of Medicine, Hebrew University, Jerusalem, Israel. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%220374236%22">Cancer</searchLink> [Cancer] 2023 Dec 15; Vol. 129 (24), pp. 3905-3914. <i>Date of Electronic Publication: </i>2023 Aug 12. – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley%22">Wiley </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>0374236 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1097-0142 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%220008543X%22">0008543X </searchLink><i>NLM ISO Abbreviation: </i>Cancer <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37572086 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1002/cncr.34985 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 3905 Titles: – TitleFull: A phase 2 study of ibrutinib maintenance following first-line high-dose methotrexate-based chemotherapy for elderly patients with primary central nervous system lymphoma. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Bairey O – PersonEntity: Name: NameFull: Taliansky A – PersonEntity: Name: NameFull: Glik A – PersonEntity: Name: NameFull: Amiel A – PersonEntity: Name: NameFull: Yust-Katz S – PersonEntity: Name: NameFull: Gurion R – PersonEntity: Name: NameFull: Zektser M – PersonEntity: Name: NameFull: Porges T – PersonEntity: Name: NameFull: Sarid N – PersonEntity: Name: NameFull: Horowitz NA – PersonEntity: Name: NameFull: Shina TT – PersonEntity: Name: NameFull: Lebel E – PersonEntity: Name: NameFull: Cohen A – PersonEntity: Name: NameFull: Geiger KR – PersonEntity: Name: NameFull: Raanani P – PersonEntity: Name: NameFull: Wolach O – PersonEntity: Name: NameFull: Siegal T IsPartOfRelationships: – BibEntity: Dates: – D: 15 M: 12 Text: 2023 Dec 15 Type: published Y: 2023 Identifiers: – Type: issn-electronic Value: 1097-0142 Numbering: – Type: volume Value: 129 – Type: issue Value: 24 Titles: – TitleFull: Cancer Type: main |
| ResultId | 1 |
